The goal of the study (‘Mercurius study') was to map the quantitative and qualitative impact of the less frequent dosing of ESA's in chronic kidney patients on haemodialysis. Hict performed this impact analysis in 40 dialysis centres over 9 European countries. The Mercurius study was later on expanded to the Canadian market.
For the analysis an impact model was developed existing of a conceptual model, a generic model and a hospital-specific model:
A calculation model was also developed in order to calculate the impact of the less frequent dosing of ESA's on the costs of the individual hospitals. The qualitative impact was defined by means of structured interviews and observations in the hospitals.